Drugs / Autologous Mesothelin-specific TCR-T Cells
Autologous Mesothelin-specific TCR-T Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04809766 | Dec 2021 → Oct 2024 | pancreatic ductal adenocarcinoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Mesothelin-specific TCR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04809766 ↗ |
| Action | Deplete | “These mesothelin-specific T cells may help the body's immune system identify and kill mesothelin+ tumor cells.” NCT04809766 ↗ |
| Modality | Cell therapy | “FH-TCR-Tᴍsʟɴ is an autologous T cell therapy targeting mesothelin” NCT04809766 ↗ |
| Route | Intravenous | “FH-TCR-Tᴍsʟɴ IV over 60-120 minutes” NCT04809766 ↗ |